HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta …
RK Gupta, J Gregson, N Parkin… - The Lancet infectious …, 2018 - thelancet.com
Background Pretreatment drug resistance in people initiating or re-initiating antiretroviral
therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might …
therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might …
Advances in developing CAR T-cell therapy for HIV cure
J Qi, C Ding, X Jiang, Y Gao - Frontiers in Immunology, 2020 - frontiersin.org
Acquired immune deficiency syndrome (AIDS), which is caused by HIV infection, is an
epidemic disease that has killed millions of people in the last several decades. Although …
epidemic disease that has killed millions of people in the last several decades. Although …
High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam
To curb HIV infection rate in Tanzania, antiretroviral therapy (ART) has been scaled up since
2006, and in 2019, the country shifted to regimen including dolutegravir as a default first line …
2006, and in 2019, the country shifted to regimen including dolutegravir as a default first line …
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …
out in low-income and middle-income countries (LMICs). In studies from predominantly high …
[图书][B] Global action plan on HIV drug resistance 2017–2021
World Health Organization - 2017 - apps.who.int
The Global Action Plan on HIV drug resistance (HIVDR) builds on the new global
commitment of the 2030 Agenda for Sustainable Development to end the AIDS epidemic by …
commitment of the 2030 Agenda for Sustainable Development to end the AIDS epidemic by …
The impact of HIV-1 drug escape on the global treatment landscape
The rising prevalence of HIV drug resistance (HIVDR) could threaten gains made in
combating the HIV epidemic and compromise the 90-90-90 target proposed by United …
combating the HIV epidemic and compromise the 90-90-90 target proposed by United …
Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency …
Abstract Background In sub-Saharan Africa, 25.5 million people are living with human
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub …
J Gregson, P Kaleebu, VC Marconi… - The Lancet infectious …, 2017 - thelancet.com
Background HIV-1 drug resistance to older thymidine analogue nucleoside reverse
transcriptase inhibitor drugs has been identified in sub-Saharan Africa in patients with …
transcriptase inhibitor drugs has been identified in sub-Saharan Africa in patients with …
Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure
A Shroufi, G Van Cutsem, V Cambiano… - Aids, 2019 - journals.lww.com
Background: Many individuals failing first-line antiretroviral therapy (ART) in sub-Saharan
Africa never initiate second-line ART or do so after significant delay. For people on ART with …
Africa never initiate second-line ART or do so after significant delay. For people on ART with …
Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya
J Kadima, E Patterson, M Mburu, C Blat, M Nyanduko… - PloS one, 2018 - journals.plos.org
Background Access to routine virologic monitoring, critical to ensuring treatment success,
remains limited in low-and middle-income countries. We report on implementation of routine …
remains limited in low-and middle-income countries. We report on implementation of routine …